Tonix Pharmaceuticals

TNXP · Nasdaq · United States

Share price · TNXP

$2.82-9.84 (-77.73%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.0M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TNXP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Nov 2026-16.3%

    Nothing announced by TNXP that day or the session before.

  2. 10 Nov 2026-8.7%
  3. 9 Nov 2026-5.3%
  4. 19 Oct 2026-5.1%
  5. 12 Oct 2026-9.0%
  6. 5 Oct 2026-9.4%
  7. 20 Jul 2026-11.7%

    Nothing announced by TNXP that day or the session before.

  8. 15 May 2026+11.7%
  9. 26 Mar 2026-8.3%
  10. 19 Mar 2026+11.1%

Share of unusual movement by asset

For each asset, the share of TNXP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
cyclobenzaprine (Tonmya)
events and moves
3719%
TNX-1500
events and moves
5shown from 8 days
Sumatriptan (Tosymra) (Tosymra)
events and moves
1shown from 8 days
TNX-1300
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—55%

Assets

(5 total)
5Total Assets
3Approved
0Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)Small molecule
Major Depressive DisorderFibromyalgia
Approved
5-HT1B/1D receptorSmall molecule
Migraine
Approved
5-HT1B/1D receptorSmall molecule
Migraine
Phase 2
Cocaine (enzymatic hydrolysis)Protein / enzyme therapeutic
Cocaine Intoxication
Phase 2
CD40 ligand (CD40L / CD154)Monoclonal antibody
Kidney Transplant Rejection

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
cyclobenzaprine · TonmyaPhase 2Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Est. primary completion 2028-02 · NCT07621237 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 August 2025ApprovalcyclobenzaprineFDA approves Tonmya for fibromyalgia
US, FDA · Source ↗
15 August 2025FDA action datecyclobenzaprinePDUFA goal date set for TNX-102 SL in fibromyalgia
US, FDA · Source ↗
6 February 2025Topline resultTNX-1500Positive topline results from Phase 1 trial of TNX-1500
17 December 2024Filing acceptedcyclobenzaprineFDA accepts NDA for TNX-102 SL for fibromyalgia
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$17M$26M$163M$53M-$41M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$14M$19M$177M$41M-$42M operating cash flowreport ↗
2026-Q1$6.9M$18M$186M$40M-$42M operating cash flowreport ↗
2025-Q3$3.3M$9.3M$191M$32M-$29M operating cash flowreport ↗
2025-Q2$2.0M$11M$126M$28M-$15M operating cash flowreport ↗
2025-Q1$2.4M$7.4M$133M$17M-$17M operating cash flowreport ↗
2024-Q3$2.8M$9.1M$29M$14M-$19M operating cash flowreport ↗
2024-Q2$2.2M$9.7M$5.1M$79M-$9.9M operating cash flowreport ↗
2024-Q1$2.5M$13M$8.0M$15M-$18M operating cash flowreport ↗
2023-Q3$4.0M$21M$7.9M$28M-$23M operating cash flowreport ↗
2023-Q2—$22M$26M$28M-$23M operating cash flowreport ↗
2023-Q1—$27M$72M$33M-$33M operating cash flowreport ↗
2022-Q3—$22M$140M$29M-$24M operating cash flowreport ↗
2022-Q2—$17M$177M$23M-$21M operating cash flowreport ↗
2022-Q1—$18M$141M$26M-$31M operating cash flowreport ↗
2021-Q3—$13M$183M$19M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$13M$44M$210M$31M-$100M operating cash flowreport ↗

Tonix Pharmaceuticals reported full-year 2025 revenue of $13.11M, up 29.9% YoY, driven largely by the TONMYA launch and existing migraine products. R&D spend was $44.49M, up 11.3% YoY, and cash and equivalents totaled approximately $207.6 million at year-end. The company recorded a net loss of $124.02M for the year.

The company expects its cash resources to fund planned operating and capital expenditure requirements into the first quarter of 2027. TONMYA was FDA-approved in August 2025 and launched on November 17, 2025, with more than 1,500 prescribers, approximately 2,500 patients initiated, and about 4,200 cumulative prescriptions through February 27, 2026. Tonix plans to initiate a U.S. field study in 2027 for TNX-4800 for seasonal prevention of Lyme disease, expects mid-2026 enrollment for the Phase 2 HORIZON study of TNX-102 SL in major depressive disorder, and completed a $20.0 million registered direct offering with Point72 in December 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$10M$40M$100M$33M-$61M operating cash flowreport ↗
2023-FY$7.8M$87M$26M$29M-$102M operating cash flowreport ↗
2022-FY—$82M$120M$28M-$98M operating cash flowreport ↗
2021-FY—$69M$179M$23M-$76M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 8 purchases ($479K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11LEDERMAN SETH · director, Chief Executive OfficerOpen-market purchase5,000$4.05$20KForm 4
2026-08-27LEDERMAN SETH · director, Chief Executive OfficerOpen-market purchase2,000$13.79$28KForm 4
2026-08-20BAGGER RICHARD H · directorOpen-market purchase1,000$12.60$13KForm 4
2026-06-30SAENGER BRADLEY · Chief Financial OfficerOther (see filing)1,453$10.91$16KForm 4
2026-06-12Taylor Carolyn E. · directorOpen-market purchase1,415$10.55$15KForm 4
2026-06-09LEDERMAN SETH · director, Chief Executive OfficerOpen-market purchase5,000$11.79$59KForm 4
2026-06-08Stillwell Richard Newcomb · directorOpen-market purchase5,000$11.65$58KForm 4
2026-05-12Taylor Carolyn E. · directorAward / grant (derivative)22,700——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 81 reporting institutions held 4.9M shares ($66.8M, 25.1% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.968,177$13.3M
2VANGUARD CAPITAL MANAGEMENT LLC518,650$7.1M
3CITADEL ADVISORS LLC468,712$6.4M
4Jones Hill Capital LP452,116$6.2M
5GEODE CAPITAL MANAGEMENT, LLC313,291$4.3M
6Balyasny Asset Management L.P.313,082$4.3M
7UBS Group AG231,678$3.2M
8STATE STREET CORP230,607$3.2M
9MILLENNIUM MANAGEMENT LLC219,673$3.0M
10AQR CAPITAL MANAGEMENT LLC161,208$2.2M
11Point72 Asset Management, L.P.125,414$1.7M
12NORTHERN TRUST CORP100,134$1.4M
13Nuveen, LLC94,561$1.3M
14VANGUARD FIDUCIARY TRUST CO84,270$1.2M
15VANGUARD PORTFOLIO MANAGEMENT LLC78,627$1.1M